구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
HER2 mAb (trastuzumab). 유방·위 HER2+ backbone. Kadcyla(T-DM1)·Enhertu(T-DXd)와 라인 시퀀싱·잔존병 전략이 비교 핵심.
First anti-HER2 mAb (trastuzumab); foundation of HER2+ breast and gastric cancer therapy before ADC era.
기전. Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
HER2
HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma
Global
Approved
herceptin · trastuzumab · Herceptin · Herzuma · Ogivri
2026-09-10
Data Confidence · High
Development Signal · Established
ADCs) are a widely used platform for developing various antican
novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT
구조화 데이터
novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT
resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes
ADCs) are a widely used platform for developing various antican
HER2 · HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines).
Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2.
ADCC by NK cells and macrophages against HER2+ cells.
apoptosis protein, is overexpressed in most tumors and is associated with drug resistance, proliferation, and metastasis, while b
HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines).
resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes
구조화 데이터
xenograft model
mouse
4
Pathologic complete response (neoadjuvant); OS in metastatic BC
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
HER2 mAb (trastuzumab). 유방·위 HER2+ backbone. Kadcyla(T-DM1)·Enhertu(T-DXd)와 라인 시퀀싱·잔존병 전략이 비교 핵심.
First anti-HER2 mAb (trastuzumab); foundation of HER2+ breast and gastric cancer therapy before ADC era.
기전. Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
HER2
HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma
Global
Approved
herceptin · trastuzumab · Herceptin · Herzuma · Ogivri
2026-09-10
Data Confidence · High
Development Signal · Established
ADCs) are a widely used platform for developing various antican
novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT
구조화 데이터
novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT
resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes
ADCs) are a widely used platform for developing various antican
HER2 · HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines).
Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2.
ADCC by NK cells and macrophages against HER2+ cells.
apoptosis protein, is overexpressed in most tumors and is associated with drug resistance, proliferation, and metastasis, while b
HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines).
resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes
구조화 데이터
xenograft model
mouse
4
Pathologic complete response (neoadjuvant); OS in metastatic BC
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.